PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
September 16, 2024 07:00 ET
|
PDS Biotechnology Corporation
Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3...
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
September 09, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting
August 08, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
August 07, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024
August 05, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
August 01, 2024 07:45 ET
|
PDS Biotechnology Corporation
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation...
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
July 31, 2024 16:01 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
July 29, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...